blosozumab blosozumab blosozumab binds sost, a negative regulator of osteoblast activity. blocking sost activity can lead to increased bone density. blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. clinical trials with blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect. blosozumabmonoclonal antibodytypewhole antibodysourcehumanized (from mouse)targetsostclinical dataatc codenoneidentifierscas number1132758-87-2 nchemspidernoneunii83yom0nel5keggd10094 nchemical and physical dataformulac6462h9852n1684o2030s46molar mass145086.42 g·mol−1 ny (what is this?) (verify) blosozumab was developed by eli lilly and company.